Abstract: Natalizumab, a monoclonal antibody that blocks lymphocyte infiltration in the central nervous system, is a valuable tool in the treatment of relapsing forms of multiple sclerosis (MS). In a phase III clinical trial comparing natalizumab with placebo over 2 years, natalizumab reduced annualized relapse rate by 68%, 12-week confirmed disability progression by 42%, and reduced contrast-enhancing lesions by 92%. In post hoc analyses, natalizumab treatment was associated with 37% of patients achieving no evidence of disease activity (versus 7% on placebo) and 30% achieving sustained disability improvement (versus 19% on placebo). Natalizumab did not achieve a statistically significant primary composite disability outcome in a trial of 887 patients with secondary progressive MS, but it did demonstrate a benefit on a prespecified component of the 9-Hole Peg Test. The greatest risk of natalizumab treatment is progressive multifocal leukoencephalopathy (PML), with a 23% mortality rate. Risk stratification on the basis of immunosuppressant exposure, natalizumab treatment duration and anti-John Cunningham virus (JCV) antibody status and index has greatly improved clinical decision making. Other potential serious natalizumab-associated risks reported in clinical trials and postmarketing settings include infusion reactions, hepatotoxicity and rare, serious opportunistic infections. With more than a decade of continuous postmarketing experience, natalizumab remains a very effective option for patients with relapsing forms of MS. To optimize appropriate selection of natalizumab for patients with relapsing MS, however, a thorough understanding of individual patient risk factors for PML or other adverse events is also required.
Introduction
As a highly effective treatment for relapsing multiple sclerosis (MS), natalizumab has provided dramatic benefits to patients with MS for more than a decade. Natalizumab prevents lymphocytes from adhering to the endothelium of the blood-brain barrier, which reduces lymphocyte infiltration into the central nervous system (CNS). Specifically, natalizumab binds onto the α 4 subunit of the α 4 β 1 integrin on the surface of lymphocytes, blocking attachment to the vascular cell adhesion molecule 1 on the vascular endothelial cells in the brain and spinal cord blood vessels. 1 The robust effect on the blood-brain barrier has led to impressive therapeutic benefits on annualized relapse rates (ARRs) and gadolinium-enhanced lesions on magnetic resonance imaging (MRI) in relapsing MS. 2 This mechanism, however, impacts immune surveillance in the CNS, as manifested in progressive multifocal leukoencephalopathy (PML). To optimize appropriate selection of natalizumab for patients with relapsing MS, a thorough understanding of individual MS patient risk factors for PML or other adverse events is required.
Phase III clinical trial results

AFFIRM: placebo-controlled trial in patients with relapsing-remitting MS
The 2-year, phase III Natalizumab Safety and Efficacy in Relapsing Remitting Multiple Sclerosis trial (AFFIRM) [ClinicalTrials.gov identifier: NCT00027300] investigated the efficacy of natalizumab in patients with relapsing-remitting MS. Using a 2:1 natalizumab to placebo randomization, 942 patients were enrolled in the study. The two prespecified primary outcomes, rate of clinical relapse at 1 year and cumulative probability of sustained progression of disability at 2 years, were met. Twelve-week confirmed disability progression occurred in 17% of patients on natalizumab and in 29% of patients on placebo, yielding a 42% relative benefit (hazard ratio 0.58; p < 0.001). The ARR at year 1 was 0.26 on natalizumab and 0.81 on placebo (68% benefit, p < 0.001). Over 2 years, the relative reduction in the ARR was maintained at 68% (0.23 on natalizumab, 0.73 on placebo; p < 0.001). 3 The AFFIRM trial also highlighted the robust effects of natalizumab on MRI assessments of disease activity. New or enlarging T2-hyperintense lesions were reduced by 83% over 2 years with natalizumab treatment compared with placebo (p < 0.001). Overall, 57% of patients on natalizumab were free of new or enlarging T2-hyperintense lesions over 2 years compared with only 15% of patients on placebo. Natalizumab treatment was associated with a 92% reduction in contrastenhanced lesions (p < 0.001). Based on an MRI scan at 2 years, a remarkable 97% of patients were free of contrast-enhanced lesions compared with 72% of patients on placebo. 3 The mean change in T1-hypointense lesion volume increased by 548 mm 3 on placebo and decreased by 1508 mm 3 on natalizumab (p < 0.001). Similarly, the reduction median percentage of change in T1-hypointense lesion volume compared with placebo over 2 years was significant (-23.5% versus -1.5%, respectively; p < 0.001). Over the 2-year study, brain parenchymal fraction (BPF) reductions were not significant between natalizumab and placebo (-0.80% and -0.82%, respectively; p = 0.822). During the first year, natalizumab-treated patients had greater brain volume loss than patients on placebo (-0.56% versus -0.40%, respectively; p = 0.002). BPF was substantially reduced with natalizumab treatment in the second year to -0.24% compared with -0.43% on placebo (p = 0.004). 4 This rate of brain volume loss on natalizumab over the second year (-0.24%) is similar to the 0.1-0.3% per year rate in healthy individuals due to age-related decline. 5 No evidence of disease activity (NEDA) is an ideal treatment goal for patients with MS. 6 In the AFFIRM trial, 37% of natalizumab-treated patients compared with 7% of placebo patients (p < 0.0001) achieved this goal. NEDA was defined as no relapses, no 12-week confirmed Expanded Disability Status Scale (EDSS) progression and no contrast-enhancing or new or enlarging T2 lesions over 2 years. 7 The highest NEDA rates were in natalizumab-treated subgroups with age younger than 35 years, disease duration less than 2 years, one or fewer relapses in the past year, EDSS less than 3.0 and no contrast-enhancing lesions on baseline scan. For those natalizumabtreated patients with one or more contrastenhancing lesion on baseline scan, 30.8% achieved NEDA at 2 years compared with only 2.2% of placebo-treated patients. 8 Natalizumab treatment also increased the likelihood of sustained disability improvement confirmed at 12 weeks. In a post hoc analysis, 29.6% of natalizumab-treated patients and 18.7% of placebo-treated patients in the AFFIRM trial had sustained disability improvement (69% relative benefit, p = 0.006). 9 The safety of natalizumab was examined in the AFFIRM study. Serious adverse events occurred in 19% of natalizumab-treated patients compared with 24% treated with placebo (p = 0.06). Relapse of MS was the most frequent serious adverse event and was more common in the placebo arm (13% versus 6% on natalizumab, p < 0.001). Adverse events reported more commonly in patients on natalizumab than placebo included headache (38% versus 33%, respectively), fatigue (27% versus 21%, respectively), arthralgia (19% versus 14%, respectively), allergic reaction (9% versus 4%, respectively) and dermatitis (7% versus 4%, respectively). Serious adverse events that occurred in less than 1% of patients receiving natalizumab but in no placebo-treated patients included anaphylactic reaction, hypersensitivity reaction, urinary tract infection and cervical dysplasia. One patient treated with natalizumab died of recurrence of malignant melanoma; in retrospect, the patient had a new skin lesion at the time of natalizumab initiation. Another patient died from alcohol intoxication after 25 doses of natalizumab. Six percent of natalizumab-treated patients developed persistent neutralizing antibodies, confirmed at least once more than 42 days apart, and had an increase in infusionrelated adverse events and a loss of efficacy of natalizumab. 
PML risk factors
The presence of serum antibodies to JCV is a known risk factor for the development of PML. Anti-JCV antibodies are detected using a twostep enzyme-linked immunosorbent assay and antibody levels are reported as an index value (titer equivalent). For patients with MS without immunosuppressant medication exposure, the median anti-JCV antibody index is higher for patients with PML than those without PML (2.4 versus 1.4, respectively; p < 0.0001). The median index values in patients with MS with prior immunosuppressant medication exposure was the same regardless of PML status (1.6 for both groups, p = 0.82). 18 The major risk factors for PML on natalizumab therapy are anti-JCV-positive status (including index), prior immunosuppressant medication use and natalizumab treatment duration. An analysis of these risk factors was performed on 32,801 natalizumab-treated patients from four large postmarketing studies. For patients who were anti-JCV antibody negative, the estimated risk was 0.1/1000 patients (95% confidence interval 0.01-0.35). Table 1 demonstrates increasing risk of PML with higher index (especially >1.5), longer treatment duration and prior immunosuppressant use (including mitoxantrone, methotrexate, azathioprine, cyclophosphamide or mycophenolate). 19, 20 Higher anti-JCV antibody index values suggests an enhanced replication of the JCV outside the kidney, such as in the brain. 21 Despite a widespread understanding of these risk factors, the overall rate of natalizumab-related PML is still increasing. 22 However, since 2013, the rate of this increased incidence of natalizumab-associated PML has slowed. 23 Only five natalizumab-treated patients with MS who developed PML were anti-JCV antibody negative prior to PML development (Biogen, personal communication, 27 October 2016). One of the cases occurred in a 70-year-old woman without immunosuppressant medication exposure who was anti-JCV antibody negative 2 weeks prior to her first symptoms of PML. 24 The estimated false negative rate of the assay for anti-JCV antibody status is 2.2%. 25 Natalizumab-treated patients with MS who are anti-JCV antibody negative are at risk of seroconversion to become anti-JCV antibody positive. 26 This rate is higher than the annualized PML rate of 1-2% in the general population. 27 Biogen has reported that the rate of seroconversion from anti-JCV antibody negative to positive and remaining positive on subsequent testing is 3-8% annually. 14 However, some cohorts have had higher seroconversion rates; annual rates from negative to positive serostatus were 10.3% in 339 German and 8.5% in 243 French patients with MS. 28 In the STRATIFY-2 study [ClinicalTrials. gov identifier: NCT01070836], rates of serostatus change to anti-JCV antibody positive were similar in patients who were or were not treated with natalizumab. 29 L-selectin (CD62L) has been proposed as another biomarker for PML risk. An unusually low percentage of CD4+ cells express CD62L on their surface in patients with MS on long-term natalizumab treatment compared with those not on natalizumab. An even lower percentage of CD62L-expressing CD4+ cells were found in patients with MS who developed natalizumabrelated PML. 30, 31 In one study using thawed peripheral blood mononuclear cells (PBMCs), low CD62L values increased a patient's relative Index >0.9-⩽1.5 Index >1. journals.sagepub.com/home/tan 331 risk of developing PML by 55-fold (p < 0.0001). 32 The use of CD62L as a biomarker for PML risk was not validated by Biogen using cryopreserved PBMCs in a study of 21 patients who developed PML and 104 matched natalizumab-treated patients without PML. Lymphocyte viability when thawed strongly affects the percentage of cells expressing CD62L. 33 
MRI monitoring
Earlier detection of PML through the use of periodic MRI scans, prior to the onset of symptoms, is associated with favorable survival and functional outcomes compared with PML diagnosis after the onset of symptoms. 16, 34 In an analysis of 372 postmarketing natalizumab PML cases as of 5 June 2013, 30 (8.1%) were classified as asymptomatic. 14 Asymptomatic PML lesions on MRI imaging are often in the frontal lobe (77.8%), unilobar (66.7%), nonenhancing (86.7%), highsignal intensity on diffusion imaging (60%) and involve the mixed cortical gray matter and juxtacortical white matter (72.2%). 15 To better detect PML early, the MAGNIMS (Magnetic Resonance Imaging in MS) study group recommended MRI screening every 3-4 months using FLAIR (fluid-attenuated inversion recovery), T2-weighted, and diffusion-weighted sequences in patients at high risk for PML (i.e. those who were anti-JCV seropositive and had treatment durations of >18 months). Anti-JCV seronegative patients should be imaged annually using the same protocol. 35 
Alternative dosing and dose interruption
To further reduce PML risk, one strategy being explored is reducing the frequency of natalizumab dosing. Based on a retrospective chart review of 2004 natalizumab-treated patients from nine US MS centers, 905 patients receiving extended dosing (ranging from every 4 weeks and 3 days to every 8 weeks and 5 days) were less likely to have new T2 lesions and relapses than 1099 patients on standard dosing. However, 10% of extendeddosing patients had contrast-enhancing lesions compared with 6% on standard dosing. The four cases of PML in this cohort were in the standard dosing patients. 36 Importantly, off-label dosing regimens have not been proven. In addition, the retrospective data analysis was not randomized, so selection bias regarding dosing frequency was introduced.
Previous attempts to reduce PML risk using 6-month planned dosing interruption backfired; 27.9% of 68 patients in one series had relapsing disease within 6 months, often with severe disability progression. 37 In the RESTORE trial [ClinicalTrials.gov identifier: NCT01071083], 46% of patients randomized to placebo for 24 weeks of dose interruption had one new contrastenhanced lesion of over 0.8 cm 3 or two or more enhanced lesions of any size compared with no patients on continuous natalizumab treatment (N = 41 for placebo, N = 45 for natalizumab). Over 24 weeks, 4% of continuous natalizumab-treated patients relapsed versus 17% on placebo. 38 Based on analysis of phase III natalizumab clinical trials and extensions, the mean number of enhancing lesions gradually increased over 6 months up to placebo-treated levels after natalizumab discontinuation. 39 Rebound or overshooting of MRI activity beyond baseline pre-natalizumab MRI activity after natalizumab discontinuation has been reported. 40 
Switching therapy from natalizumab
If a patient becomes anti-JCV antibody positive on natalizumab treatment or has a rising antibody index, both the clinician and the patient should jointly discuss the risks and benefits of continuing natalizumab or switching therapy. Switching to an alternative disease-modifying therapy (DMT) carries the risk of development of worsening longterm disability progression. 41 However, patients must understand the full consequences of the risk of PML, including death, versus the risk of worsening, and potentially permanent, disability.
Switching from natalizumab to fingolimod has been investigated in multicenter trials consisting of more than 70% of patients with anti-JCV antibody positive MS. Relapses during the transition were lowest, with a 12-week or less washout, and active MRI lesions were lowest with an 8-week washout. 42, 43 In an Italian multicenter, prospective, observational cohort, the cumulative probability of a first relapse 1 year after switching from natalizumab to fingolimod was 15.01% compared with 26.84% after switching to interferon or glatiramer acetate. 44 LaGanke et al. reported no relapses in switching 200 patients from natalizumab to alemtuzumab at their center. Of the 162 patients with EDSS measurements, EDSS improved in 69 patients and worsened in 2 patients switched to alemtuzumab. Only 3 out of 160 patients had new FLAIR lesions on MRI imaging. 45 MRI imaging to screen for pre-existing PML prior to switching to alemtuzumab is important since a death occurred in this clinical setting. 46 Based on Swedish register data of 256 patients switched from natalizumab due to anti-JCV antibody positive status, fewer relapses occurred in the cohort switched to rituximab than fingolimod (1.8% versus 17.6%) over 1.5 years after the cessation of natalizumab. Contrast-enhancing lesions were also less common on rituximab versus fingolimod (1.4% versus 24.2%). 47 Rituximab, however, lacks regulatory approval for MS. Analysis of a trial switching patients from natalizumab to dimethyl fumarate reported a 19.6% risk of protocol-defined relapse over 1 year in 506 patients. The ARR was 0.114 on natalizumab and 0.248 on dimethyl fumarate. 48 Daclizumab is also being studied in a natalizumab-switch study [ClinicalTrials. 55 Of the 496 patients who completed 4 years of natalizumab treatment, 83.5% of patients remained free of 24-week confirmed disability over 4 years (10.9% had progressive disease over months 0-24 and 6.3% over months . 56 This ongoing 10-year observational study also provides insight into the safety profile of natalizumab. Out of the 4821 patients enrolled, 18 developed PML, with 89% survival. Twelve other serious opportunistic infections were reported, including two cases of herpes meningitides, two cases of herpes zoster and two cases of pneumonia. Twenty-four patients developed 12 types of malignancies, including 7 cases of breast cancer. The causes of the nine deaths were three suicides, two pulmonary emboli and single cases each of urosepsis (in a patient with PML), drowning, autonomic nervous system imbalance and thermal burn. 54 Effectiveness of natalizumab has also been evaluated using global cohorts such as MSBase. In an analysis of propensity-matched patients with relapsing-remitting MS, natalizumab treatment was associated with ARRs similar to alemtuzumab but lower than fingolimod and interferon β. Hepatotoxicity Natalizumab may have direct hepatic toxic effects, as postmarketing hepatotoxicity has been reported, including cases of hepatic failure. An increased number of circulating autoreactive immune cells with natalizumab treatment may unmask autoimmune hepatitis. 60 Of 4938 patients with MS in the TYGRIS study, hepatotoxic events occurred in six patients, including four with confounders or an alternative cause. 53 One 28-year-old patient on natalizumab died from either reactivation of or acute infection with hepatitis B virus. 61 
Conclusion
The therapeutic options to treat relapsing forms of MS have greatly expanded over the past two decades. With the introduction of monoclonal antibody treatments, multiple highly effective options are available to help reduce the risk of disability for those living with MS. 62 Understanding the mechanism of action of each monoclonal antibody therapy and its duration of immunological impact is critical for treatment selection for each patient.
In terms of long-term safety and efficacy of intravenous monoclonal antibody therapies in MS, the full profile for alemtuzumab is being established and data collection on ocrelizumab is just beginning. [63] [64] [65] With more than a decade of postmarketing experience in more than 167,300 patients (as of February 2017), the benefit to risk ratio of natalizumab has been robustly characterized. Clinical studies have demonstrated the substantial efficacy of natalizumab, 3, 9 but risks associated with natalizumab treatment, such as PML, have also been identified. Stratification of PML risk, including assessment of anti-JCV antibody status with index testing, is a key component to help guide healthcare providers and patients with MS as to when to initiate or continue natalizumab treatment. While the array of therapies for MS keeps rapidly growing, natalizumab has continued and will continue to be a highly important option in preventing disability in people living with MS.
